中文摘要：

目的 建立检测外周血单个核细胞α干扰素受体1（IFNAR1）及检测诱导表达α干扰素（IFN-α）的方法,评价慢性丙型肝炎患者外周血单个核细胞（PBMC）细胞免疫功能与α干扰素治疗的关系.方法 Poly IC体外刺激正常对照组和慢性丙型肝炎病毒（HCV）感染组患者PBMC,利用病毒保护试验研究干扰素治疗前后患者PBMC表达的干扰素抗病毒生物学活性差异;IFN-α治疗前后,RT-PCR检测慢性丙型肝炎患者不同干扰素应答组患者PBMC IFNAR1表达的变化.结果 对照组PBMC分泌的干扰素活性显著高于慢性丙型肝炎患者应答组患者（P〈0.001）;干扰素应答组患者PBMC分泌的干扰素活性随治疗时间延长而增加,治疗1个月后显著高于无应答组患者PBMC分泌的干扰素活性（P〈 0.01）,后者始终处于低下水平;IFN-α治疗期间干扰素应答组患者PBMC IFNAR1水平从治疗前的高表达而逐渐减少,正常对照和干扰素无应答组患者PBMC IFNAR1的表达始终较低.结论 慢性HCV感染患者的细胞免疫功能受损,不能正常表达IFN-α,但应答组患者经干扰素治疗后IFN-α表达能力逐渐恢复;干扰素无应答组患者PBMC IFNAR1表达受到严重抑制;慢性丙型肝炎患者PBMCIFN-α活性检测及IFNAR1检测结果也许可以作为干扰素治疗预后的判断指标.

英文摘要：

OBJECTIVE To investigate the relationship between expression of interferon-α receptor 1 （IFNAR1）in peripheral blood mononuclear cells （PBMC） and the response to interferon-α （IFN-α） therapy of patients with chronic hepatitis C, and analyze the cellular immune status of patients with chronic hepatitis C virus （ HCV ） infection. METHODS PBMC of chronic HCV infected patients were cultured, then detected antiviral biological activity of culture supernatants from PBMC stimulated with high concentration Poly IC by viral protection assay. IFNAR1 mRNAs from PBMC of patients with chronic HCV infection were measured by reverse transcription- polymerase chain reaction （RT-PCR）. RESULTS The data indicated that it existed lower titer of interferon from Poly IC induced PBMC of chronic HCV infected patients. Responder enhanced activity of IFN-α from PBMC stimulated by Poly IC after treated with IFN-α, however, non-responder continuously kept lower activity of IFN-α from PBMC. The expression of IFNAR1 mRNA in PBMC from non-responder to IFN-α was inhibited, in contrast with it, responder presented a high level of expression of IFNAR1 mRNA before treatment of IFN-α, and IFNAR1 mRNA expression decreased after treated with IFN-α. CONCLUSIONS The cellular immune function of patients with chronic HCV infection is impaired. The expression of IFNAR1 gene of non-responder of chronic HCV infected patients is inhibited. The IFN-α activity and IFNAR1 mRNA level of PBMC perhaps can be markers for hepatitis C prognosis after IFN-α therapy for chronic hepatitis C patients.